308 related articles for article (PubMed ID: 27586402)
1. Long term outcome of Aldosteronism after target treatments.
Wu VC; Wang SM; Chang CH; Hu YH; Lin LY; Lin YH; Chueh SC; Chen L; Wu KD
Sci Rep; 2016 Sep; 6():32103. PubMed ID: 27586402
[TBL] [Abstract][Full Text] [Related]
2. Influence of Different Treatment Strategies on New-Onset Atrial Fibrillation Among Patients With Primary Aldosteronism: A Nationwide Longitudinal Cohort-Based Study.
Pan CT; Liao CW; Tsai CH; Chen ZW; Chen L; Hung CS; Liu YC; Lin PC; Chang CC; Chang YY; Wu VC; Lin YH;
J Am Heart Assoc; 2020 Mar; 9(5):e013699. PubMed ID: 32070205
[TBL] [Abstract][Full Text] [Related]
3. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years.
Wu VC; Chueh SJ; Chen L; Chang CH; Hu YH; Lin YH; Wu KD; Yang WS;
J Hypertens; 2017 Aug; 35(8):1698-1708. PubMed ID: 28661412
[TBL] [Abstract][Full Text] [Related]
4. Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments.
Wu VC; Wang SM; Huang KH; Tsai YC; Chan CK; Yang SY; Lin LY; Chang CC; Lu CC; Lin YH; Chen YM; Chueh JS
Eur J Endocrinol; 2021 Dec; 186(2):195-205. PubMed ID: 34851859
[TBL] [Abstract][Full Text] [Related]
5. Surgery decreases the long-term incident stroke risk in patients with primary aldosteronism.
Chang YH; Chung SD; Wu CH; Chueh JS; Chen L; Lin PC; Lin YH; Huang KH; Wu VC; Chu TS;
Surgery; 2020 Feb; 167(2):367-377. PubMed ID: 31676114
[TBL] [Abstract][Full Text] [Related]
6. Risk of Fracture in Primary Aldosteronism: A Population-Based Cohort Study.
Wu VC; Chang CH; Wang CY; Lin YH; Kao TW; Lin PC; Chu TS; Chang YS; Chen L; Wu KD; Chueh SJ
J Bone Miner Res; 2017 Apr; 32(4):743-752. PubMed ID: 27862274
[TBL] [Abstract][Full Text] [Related]
7. Administrative data on diagnosis and mineralocorticoid receptor antagonist prescription identified patients with primary aldosteronism in Taiwan.
Wu VC; Hu YH; Wu CH; Kao CC; Wang CY; Yang WS; Lee HH; Chang YS; Lin YH; Wang SM; Chen L; Wu KD;
J Clin Epidemiol; 2014 Oct; 67(10):1139-49. PubMed ID: 25034196
[TBL] [Abstract][Full Text] [Related]
8. Risk of sepsis in patients with primary aldosteronism.
Chan CK; Hu YH; Chen L; Chang CC; Lin YF; Lai TS; Huang KH; Lin YH; Wu VC; Wu KD;
Crit Care; 2018 Nov; 22(1):313. PubMed ID: 30463626
[TBL] [Abstract][Full Text] [Related]
9. Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry.
Parra Ramírez P; Martín Rojas-Marcos P; Paja Fano M; González-Boillos M; Pascual-Corrales E; García Cano AM; Ruiz-Sanchez JG; Vicente Delgado A; Gómez Hoyos E; Ferreira R; García Sanz I; Recasens Sala M; Barahona San Millan R; Picón César MJ; Díaz Guardiola P; Perdomo CM; Manjón-Miguélez L; Rebollo Román Á; Robles Lázaro C; Morales-Ruiz M; Calatayud M; Andree Furio Collao S; Meneses D; Sampedro-Nuñez MA; Mena Ribas E; Sanmartín Sánchez A; Gonzalvo Diaz C; Lamas C; Guerrero-Vázquez R; Del Castillo Tous M; Serrano Gotarredona J; Michalopoulou Alevras T; Tenés Rodrigo S; Roa Chamorro R; Jaen Aguila F; Moya Mateo EM; Hanzu FA; Araujo-Castro M
High Blood Press Cardiovasc Prev; 2024 Jan; 31(1):43-53. PubMed ID: 38225508
[TBL] [Abstract][Full Text] [Related]
10. Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
Hypertension; 2018 Sep; 72(3):658-666. PubMed ID: 29987110
[TBL] [Abstract][Full Text] [Related]
11. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies.
Marzano L; Colussi G; Sechi LA; Catena C
Am J Hypertens; 2015 Mar; 28(3):312-8. PubMed ID: 25336498
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Outcomes with Surgical and Medical Management of Primary Aldosteronism.
Wachtel H; Fraker DL
Curr Cardiol Rep; 2021 Jun; 23(7):89. PubMed ID: 34081226
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis.
Chen SY; Chen JY; Huang WC; Puar THK; Chin Kek P; Chueh JS; Lin YH; Wu VC; Study Group T
Eur J Endocrinol; 2022 Dec; 187(6):S47-S58. PubMed ID: 36315466
[TBL] [Abstract][Full Text] [Related]
14. Risk of new-onset autoimmune diseases in primary aldosteronism: a nation-wide population-based study.
Er LK; Chen L; Tsai YC; Lin YH; Huang WC; Chang CC; Lu CC; Huang KH; Chueh JS; Wu KD; Wu VC;
J Hypertens; 2020 Apr; 38(4):745-754. PubMed ID: 31764584
[TBL] [Abstract][Full Text] [Related]
15. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism.
Park KS; Kim JH; Yang YS; Hong AR; Lee DH; Moon MK; Choi SH; Shin CS; Kim SW; Kim SY
Endocr J; 2017 Jun; 64(6):623-632. PubMed ID: 28458337
[TBL] [Abstract][Full Text] [Related]
16. Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term.
Rossi GP; Maiolino G; Flego A; Belfiore A; Bernini G; Fabris B; Ferri C; Giacchetti G; Letizia C; Maccario M; Mallamaci F; Muiesan ML; Mannelli M; Negro A; Palumbo G; Parenti G; Rossi E; Mantero F;
Hypertension; 2018 Apr; 71(4):585-591. PubMed ID: 29483224
[TBL] [Abstract][Full Text] [Related]
17. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
Riester A; Reincke M
Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
[TBL] [Abstract][Full Text] [Related]
18. Worsening of lipid metabolism after successful treatment of primary aldosteronism.
Adolf C; Asbach E; Dietz AS; Lang K; Hahner S; Quinkler M; Rump LC; Bidlingmaier M; Treitl M; Ladurner R; Beuschlein F; Reincke M
Endocrine; 2016 Oct; 54(1):198-205. PubMed ID: 27179655
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
JAMA Cardiol; 2018 Aug; 3(8):768-774. PubMed ID: 30027227
[TBL] [Abstract][Full Text] [Related]
20. Changes in Glucose Metabolism after Adrenalectomy or Treatment with a Mineralocorticoid Receptor Antagonist for Primary Aldosteronism.
Lin YF; Peng KY; Chang CH; Hu YH; Wu VC; Chung SD;
Endocrinol Metab (Seoul); 2020 Dec; 35(4):838-846. PubMed ID: 33261310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]